Samil Pharmaceutical Co.,Ltd

000520.KS

000520.KSSamil Pharmaceutical Co.,Ltd

KSE

12,900.00

KRW

+700.00

(+5.74%)

262.85BMarket Cap

Nov 13Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

KR7000520007

Return %

Stock

S&P500

77.44

24.79

51.28

26.53

32.00

87.24

Use logarithmic scale

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	7,959.67	7,701.37	7,517.42	7,289.92	7,566.8	8,340.96	7,915.88	8,140.25	9,031.74	9,147.38	9,701.02	11,548.9	13,691.36	14,526.74
Basic EPS, GAAP	-571.11	-244.22	668.09	-954.48	50.51	76.43	-108.93	-736.82	58.64	99.7	-386.36	-1.82	116	-79.63
Free Cash Flow per Basic Share	-798.69	251.51	-494.73	-1,510.46	32.96	101.88	-3,401.43	-562.56	-290.14	-701.77	-2,288.84	-2,860.44	-881.75	-585.84
Dividend per Share	- -	65.86	65.89	66.71	87.63	87.99	65.84	65.87	45.52	68.34	67.83	64.35	- -	- -
Book Value per Share	5,769.35	5,453.82	6,057.22	4,968.71	4,891.21	4,778.5	4,621.04	3,460.83	2,901.47	3,103.33	2,493.73	2,150.81	2,484.65	- -
Tangible Book Value per Share	5,039.46	4,760.04	5,474.16	4,556.65	4,498.92	4,380.55	4,265.99	4,690.67	4,514.96	4,597.91	4,657.42	7,885.61	8,716.96	12,019.35
Basic Weighted Avg Shares	12	12	12	12	12	12	12	12	13	13	14	16	14	15
Sales/Revenue/Turnover	94,476	91,444	89,229	85,461	88,136	96,758	92,038	94,600	121,107	122,999	134,247	179,676	196,346	210,733
Operating Margin (%)	-9.28	-1.72	-2.22	-10.08	1.82	3.98	1.42	-6.06	3.98	5.32	0.3	2.24	3.3	12.5
Depreciation Expense	3,651	3,641	3,528	3,412	3,039	3,147	3,643	3,686	4,016	4,199	4,712	4,989	5,368	4,071
Net Income, GAAP	-6,779	-2,900	7,930	-11,190	588	887	-1,267	-8,563	786	1,341	-5,347	-28	1,664	-1,155
Effective Tax Rate (%)	- -	- -	35.14	- -	44.14	66.77	- -	- -	45.98	- -	- -	102.67	- -	140.23
Profit Margin (%)	-7.18	-3.17	8.89	-13.09	0.67	0.92	-1.38	-9.05	0.65	1.09	-3.98	-0.02	0.85	-0.55
Working Capital	6,285	24,595	30,035	20,381	14,292	12,768	-252	-26,136	11,044	-26,160	-44,964	-57,811	-87,560	-29,587
LT Debt	- -	7,000	- -	8,000	- -	2,000	27,000	- -	45,280	20,307	32,914	73,304	50,794	- -
Total Equity	66,604	62,874	70,027	55,415	54,410	52,871	51,167	56,083	62,272	63,551	65,746	125,820	127,827	174,359
Return on Invested Capital (%)	- -	- -	-1.33	- -	1.03	1.54	- -	- -	1.87	- -	- -	-0.04	- -	-4.47
Return on Capital (%)	- -	- -	9.15	- -	1.4	1.46	- -	- -	2.42	- -	- -	-0.08	- -	-2.05
Return on Common Equity (%)	-9.59	-4.35	11.61	-17.2	1.02	1.58	-2.32	-18.23	1.99	3.33	-14.03	-0.08	4.82	-6.28

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	8.84%	16.37%	9.28%
Net Income, GAAP	-658.04%	-1,323.58%	-5,980.93%
Free Cash Flow	-291.61%	61.33%	-71.59%
Total Cash Common Dividend	- -	- -	- -
Total Equity	9.04%	21.9%	1.6%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Mr. Kang Huh
Full Time Employees: 575
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Address: 155 Hyoryeong-Ro Seoul South Korea
IPO Date: Invalid Date
Website: www.samil-pharm.com
Business: Samil Pharmaceutical Co.,Ltd engages in the manufacture and sale of indispensable medicines in South Korea. It offers hepatic, gastrointestinal, vasodilator, antithrombotic, respiratory, skeletal muscle relaxants, circulatory, neurological, antibiotics, metabolic, antihistamines, immunosuppressive, hormone, anti-tumor, urinary, and ophthalmic drugs, as well as antipyretic, analgesic, and anti-inflammatory agents. The company also provides OTC products and sanitary aids. Samil Pharmaceutical Co.,Ltd was founded in 1947 and is headquartered in Seoul, South Korea.

	Dec'23	Mar'24	Jun'24
Total Current Assets	81,115	79,341	84,694
Accounts Receivable, Net	35,813	36,684	- -
Cash, Cash Equivalents & STI	906	1,717	- -
Inventories	32,511	28,290	- -
Total Current Liabilities	168,675	112,651	114,281
Payables & Accruals	- -	- -	- -
ST Debt	125,086	77,806	- -
Deferred Revenue	- -	- -	- -

	Dec'23	Mar'24	Jun'24
ST Debt	125,086	77,806	- -
LT Borrowings	49,568	77,045	- -
LT Finance Leases	1,225	1,471	- -
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	14	18	18
Market Capitalization	92,357	167,124	119,969

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	7,959.67	7,701.37	7,517.42	7,289.92	7,566.8	8,340.96	7,915.88	8,140.25	9,031.74	9,147.38	9,701.02	11,548.9	13,691.36	14,526.74
Basic EPS, GAAP	-571.11	-244.22	668.09	-954.48	50.51	76.43	-108.93	-736.82	58.64	99.7	-386.36	-1.82	116	-79.63
Free Cash Flow per Basic Share	-798.69	251.51	-494.73	-1,510.46	32.96	101.88	-3,401.43	-562.56	-290.14	-701.77	-2,288.84	-2,860.44	-881.75	-585.84
Dividend per Share	- -	65.86	65.89	66.71	87.63	87.99	65.84	65.87	45.52	68.34	67.83	64.35	- -	- -
Book Value per Share	5,769.35	5,453.82	6,057.22	4,968.71	4,891.21	4,778.5	4,621.04	3,460.83	2,901.47	3,103.33	2,493.73	2,150.81	2,484.65	- -
Tangible Book Value per Share	5,039.46	4,760.04	5,474.16	4,556.65	4,498.92	4,380.55	4,265.99	4,690.67	4,514.96	4,597.91	4,657.42	7,885.61	8,716.96	12,019.35
Basic Weighted Avg Shares	12	12	12	12	12	12	12	12	13	13	14	16	14	15
Sales/Revenue/Turnover	94,476	91,444	89,229	85,461	88,136	96,758	92,038	94,600	121,107	122,999	134,247	179,676	196,346	210,733
Operating Margin (%)	-9.28	-1.72	-2.22	-10.08	1.82	3.98	1.42	-6.06	3.98	5.32	0.3	2.24	3.3	12.5
Depreciation Expense	3,651	3,641	3,528	3,412	3,039	3,147	3,643	3,686	4,016	4,199	4,712	4,989	5,368	4,071
Net Income, GAAP	-6,779	-2,900	7,930	-11,190	588	887	-1,267	-8,563	786	1,341	-5,347	-28	1,664	-1,155
Effective Tax Rate (%)	- -	- -	35.14	- -	44.14	66.77	- -	- -	45.98	- -	- -	102.67	- -	140.23
Profit Margin (%)	-7.18	-3.17	8.89	-13.09	0.67	0.92	-1.38	-9.05	0.65	1.09	-3.98	-0.02	0.85	-0.55
Working Capital	6,285	24,595	30,035	20,381	14,292	12,768	-252	-26,136	11,044	-26,160	-44,964	-57,811	-87,560	-29,587
LT Debt	- -	7,000	- -	8,000	- -	2,000	27,000	- -	45,280	20,307	32,914	73,304	50,794	- -
Total Equity	66,604	62,874	70,027	55,415	54,410	52,871	51,167	56,083	62,272	63,551	65,746	125,820	127,827	174,359
Return on Invested Capital (%)	- -	- -	-1.33	- -	1.03	1.54	- -	- -	1.87	- -	- -	-0.04	- -	-4.47
Return on Capital (%)	- -	- -	9.15	- -	1.4	1.46	- -	- -	2.42	- -	- -	-0.08	- -	-2.05
Return on Common Equity (%)	-9.59	-4.35	11.61	-17.2	1.02	1.58	-2.32	-18.23	1.99	3.33	-14.03	-0.08	4.82	-6.28

Year	Q1	Q2	Q3	Q4	FY
2022	45,850	44,966	45,397	43,462	179,676
2023	45,740	48,460	51,630	50,516	196,346
2024	54,299	54,288	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	24.55	-18.18	-138.18	- -	-1.82
2023	55	50.47	-46.12	- -	116
2024	-118	- -	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	- -	- -	2.62	- -	64.35
2023	- -	- -	- -	- -	- -
2024	- -	- -	- -	- -	- -

Samil Pharmaceutical Co.,Ltd

Growth Rates

(avg. rate of change)

Company Description

Working Capital

Capital Structure

Growth Rates

(avg. rate of change)

Quarterly Revenue

Year

Quarterly Earnings Per Share

Year

Quarterly Dividends Per Share

Year